Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares were up 3.2% during mid-day trading on Monday . The company traded as high as $2.29 and last traded at $2.27, with a volume of 84,943 shares changing hands. The stock had previously closed at $2.20.

A number of research analysts have issued reports on CNAT shares. Roth Capital started coverage on shares of Conatus Pharmaceuticals in a report on Friday, July 1st. They issued a “buy” rating for the company. Brean Capital reaffirmed a “buy” rating and issued a $7.00 target price (down from $13.00) on shares of Conatus Pharmaceuticals in a report on Monday, May 9th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a report on Sunday, May 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $9.66.

The firm has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.18. The firm’s market capitalization is $49.74 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). During the same quarter in the prior year, the company posted ($0.38) EPS. Equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.53) earnings per share for the current year.

A hedge fund recently raised its stake in Conatus Pharmaceuticals stock. Jennison Associates boosted its position in shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned about 3.32% of Conatus Pharmaceuticals worth $2,933,000 as of its most recent filing with the SEC.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.